Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms.
Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haemato-oncologists with a decent practice in lymphoma therapy, who have not yet used ibritumomab themselves. It summarizes clinical trials with radioimmunotherapy, indicating clinical situations where it may be specifically useful.
Jurczak
Wojciech
W
Department of Haematology, Collegium Medicum, Jagiellonian University, Kraków, Poland. wj2004@wp.pl
Hubalewska-Dydejczyk
Alicja
A
Giza
Agnieszka
A
Sowa-Staszczak
Anna
A
Huszno
Bohdan
B
Skotnicki
Aleksander B
AB
D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends*; D020000:Decision Support Systems, Clinical; D005060:Europe; D006801:Humans; D008223:Lymphoma / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000639:trends*; D019275:Radiopharmaceuticals / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D019275:Radiopharmaceuticals; C422802:ibritumomab tiuxetan